search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
SKIN CARE


47


D0


D28 Figure 5: Visual inspection of the biopeptide complex eye cream administration site at the start and end of the trial


control group (Figure 3D). The test group showed a significant increase in skin firmness at D28, indicating improved skin firmness and resilience. Dermal intensity, reflecting collagen


content in the skin, improved by 10.60% at D28 in the test group, compared to a 3.94% decrease in the control group (Figure 3E). The test group showed a significant improvement in dermal intensity at D28, indicating increased skin protein content (Figure 4).


The improvement in skin condition is visually observed (Figure 5). At the end of the trial, none of the individuals in the test group and the control group has adverse reaction to the test products.


Conclusion Zellulin ZelluGen is a biopeptide complex that instructs skin cells to synthesize more ECM, the skin’s structural foundation. It is produced


at an ISO22716-certified facility using a novel, sustainable process with full traceability. Zellulin ZelluGen is proven to renew,


protect and maintain youthful skin. It is water- soluble and suitable for use as an advanced multifunctional active ingredient within anti- ageing formulations.


Editor’s Note A full list of references can be found online at https://tinyurl.com/5af6burb


PC


www.personalcaremagazine.com


May 2025 PERSONAL CARE


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96